Swiss National Bank Fate Therapeutics Inc Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Swiss National Bank holds 166,700 shares of FATE stock, worth $403,414. This represents 0.0% of its overall portfolio holdings.

Number of Shares

166,700

Previous 179,100 6.92%

Holding current value

$403,414

Previous $587,000 0.68%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$3.12 - $5.57 $38,688 - $69,068	-12,400 Reduced 6.92%	166,700 $583,000
Q2 2024 Aug 08, 2024	BUY	$3.26 - $7.08 $583,866 - $1.27 Million	179,100 New	179,100 $587,000
Q2 2023 Aug 09, 2023	BUY	$4.76 - $6.59 $15,232 - $21,088	3,200 Added 1.91%	171,000 $813,000
Q1 2023 May 10, 2023	SELL	$4.24 - $11.12 $83,104 - $217,951	-19,600 Reduced 10.46%	167,800 $956,000
Q4 2022 Feb 08, 2023	BUY	$9.86 - $23.83 $40,426 - $97,703	4,100 Added 2.24%	187,400 $1.89 Million
Q3 2022 Nov 09, 2022	BUY	$21.04 - $36.06 $33,664 - $57,696	1,600 Added 0.88%	183,300 $4.11 Million
Q2 2022 Aug 09, 2022	BUY	$17.78 - $42.39 $19,558 - $46,629	1,100 Added 0.61%	181,700 $4.5 Million
Q1 2022 May 09, 2022	BUY	$29.67 - $60.28 $388,677 - $789,668	13,100 Added 7.82%	180,600 $7 Million
Q4 2021 Feb 08, 2022	BUY	$47.84 - $64.34 $62,192 - $83,642	1,300 Added 0.78%	167,500 $9.8 Million
Q3 2021 Nov 08, 2021	BUY	$59.27 - $95.73 $47,416 - $76,584	800 Added 0.48%	166,200 $9.85 Million
Q2 2021 Aug 06, 2021	BUY	$67.25 - $92.52 $403,500 - $555,120	6,000 Added 3.76%	165,400 $14.4 Million
Q1 2021 May 07, 2021	BUY	$72.16 - $117.4 $165,968 - $270,020	2,300 Added 1.46%	159,400 $13.1 Million
Q4 2020 Feb 05, 2021	BUY	$38.09 - $100.95 $617,058 - $1.64 Million	16,200 Added 11.5%	157,100 $14.3 Million
Q3 2020 Nov 09, 2020	BUY	$30.41 - $40.5 $182,460 - $243,000	6,000 Added 4.45%	140,900 $5.63 Million
Q2 2020 Aug 05, 2020	BUY	$20.21 - $35.23 $355,696 - $620,048	17,600 Added 15.0%	134,900 $4.63 Million
Q1 2020 May 08, 2020	BUY	$17.28 - $31.88 $69,120 - $127,520	4,000 Added 3.53%	117,300 $2.61 Million
Q4 2019 Feb 06, 2020	BUY	$13.39 - $20.73 $32,136 - $49,752	2,400 Added 2.16%	113,300 $2.22 Million
Q3 2019 Nov 12, 2019	BUY	$15.47 - $22.5 $228,956 - $333,000	14,800 Added 15.4%	110,900 $1.72 Million
Q2 2019 Aug 02, 2019	BUY	$15.61 - $20.44 $32,781 - $42,924	2,100 Added 2.23%	96,100 $1.95 Million
Q1 2019 May 10, 2019	BUY	$13.15 - $18.71 $69,695 - $99,163	5,300 Added 5.98%	94,000 $1.65 Million
Q4 2018 Feb 13, 2019	BUY	$11.48 - $16.98 $26,404 - $39,054	2,300 Added 2.66%	88,700 $1.14 Million
Q3 2018 Nov 08, 2018	BUY	$8.75 - $16.29 $112,875 - $210,141	12,900 Added 17.55%	86,400 $1.41 Million
Q2 2018 Aug 09, 2018	BUY	$9.16 - $13.48 $673,260 - $990,780	73,500 New	73,500 $833,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $235M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Fate Therapeutics Inc Transaction History